title: [Treatment of initial urinary tract infection in children with cotrifamole and cotrimoxazole. A double-blind study].
abstract: 28 children with initial episodes of urinary tract infection were treated with cotrimoxazole or cotrifamole (dose ratio 3 : 2) for 14 days in a prospective randomized double blind trial. The two groups did not differ as regards clinical signs. The efficacy and cure rates of each regimen were similar. Laboratory studies (hemoglobin, WBC, liver, and renal function) showed no differences between both groups before and after therapy; an alteration of the laboratory values could not be observed during therapy. The number of children with X-ray abnormalities of kidneys and urinary tract was similar in both groups. During an observation time of up to 12 months after the first urinary tract infection no differences in the number of reinfections and relapses were observed. As a result of this study, we recommend cotrifamole in a lower dose (ratio 2 : 3) than cotrimoxazole for the treatment of urinary tract infection.
mesh_terms: D000293:Adolescent; D000892:Anti-Infective Agents, Urinary / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D004338:Drug Combinations / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D011859:Radiography; D011897:Random Allocation; D012008:Recurrence; D013420:Sulfamethoxazole / Q000627:therapeutic use*; D013423:Sulfamoxole / Q000627:therapeutic use*; D014295:Trimethoprim / Q000627:therapeutic use*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014552:Urinary Tract Infections / Q000000981:diagnostic imaging / Q000188:drug therapy*
chemical_list: D000892:Anti-Infective Agents, Urinary; D004338:Drug Combinations; C013268:sulfamoxole, trimethoprim drug combination; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013423:Sulfamoxole; D013420:Sulfamethoxazole
vernacular_title: Behandlung von ersten Harnwegsinfekten im Kindesalter mit Cotrifamol und Cotrimoxazol.